Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

332 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Inventiveness Of Chinese Second Medical Use Patent: A Study From Top 10 Exemplary Invalidation Case

    Second medical use of a known compound is an important invention to the pharmaceutical industry.
    ChinaIntellectual Property
    Foundin Intellectual Property
    Foundin Intellectual Property
  • Article

    中国、2020年欧州特許庁での特許出願が過去最多に

    欧州特許庁が16日に発表したデータによると、2020年中国からあった特許出願件数は過去最多となる前年比9.9%増の1万3432件だった。
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

Avoid the Anti-Corruption "Blacklist:" Chinese Agency Guidance

On March 1, 2014, Circular No. 50 went into effect, promulgated to regulate the conduct of pharmaceutical and medical device companies that do business in China.
ChinaFood, Drugs, Healthcare, Life Sciences
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
  • Article

    China's State Council Publishes New Regulations On The Management Of Human Genetic Resources

    China's State Council, the country's top administrative authority, released a new Regulation of Human Genetic Resources1 (the "Regulation") on May 28, 2019, to replace the tentative rules issued
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    Chinese Regulators Publish Final Anti-Corruption Guidelines For The Healthcare Industry

    On January 14, 2025, the State Administration for Market Regulation (SAMR, 国家市场监督管理总局) published the Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Article

    Chinese FDA Unveils Plan For Regulatory Reform

    The Chinese State Food and Drug Administration announced a plan for regulatory reform and is soliciting public comments through January 15, 2013.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    China's FDA Proposes Patent Linkage Mechanism and Terms for Data Exclusivity for Public Comments

    The China Food and Drug Administration on May 12 proposed for the public's comments a draft regulation entitled Relevant Policies for Encouraging Innovations on Drugs and Medical Devices and Protecting Innovators' Rights and Interests ...
    ChinaIntellectual Property
    Lexfield Law Offices
    Lexfield Law Offices
  • Article

    Tips For Pharmaceutical Use Claims

    In China, a method for treating or diagnosing a disease cannot be granted for a patent right. Generally speaking, we suggest amending this kind of claims into Swiss-type claims...
    ChinaIntellectual Property
    Chang Tsi & Partners
    Chang Tsi & Partners
  • Article

    China FDA Updates The Medical Device Classification Catalogue

    In China, medical devices are divided into three regulatory classes based on the identified risks associated with the devices.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    中国初の脳血栓吸引カテーテルシステムが認可

    中国初の国産脳血栓吸引カテーテルシステム「AfenttaTM」が、国家薬品監督管理局から販売を認可された。このイノベーション製品は独自の知的
    ChinaFood, Drugs, Healthcare, Life Sciences
    Kangxin
    Kangxin
  • Article

    広東の創薬と電池リサイクル企業、国際知財賞で最終候補に

    広州市の創薬ベンチャー、広東衆生睿創がWIPOグローバル・アワード2026のファイナリストに選出され、中国から計6社が入選。また、広東邦普循環科
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    China's Supreme Court Issued A New Draft On The Trial Of Cases Involving Infringement Of New Plant Variety Rights

    On March 23, 2021, the Supreme People's Court ("SPC") issued "Provisions of the Supreme People's Court on Several Issues Concerning the Application...
    ChinaFood, Drugs, Healthcare, Life Sciences
    BUREN
    BUREN
  • Article

    China Proposed Draft Implementing Rules For Human Genetic Resources Management

    On March 21, 2022, the Ministry of Science and Technology of the People's Republic of China published the Implementing Rules for Human Genetic Resources Management (draft for comment) ...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Sheppard
    Sheppard
  • Article

    Chinese FDA Soliciting Public Comments On Rules For Re-Packaging Of IVDs

    The State Food and Drug Administration ("SFDA") in China published a draft of the Tentative Measures for the Administration of the Registration of Re-Packaging In-Vitro Devices (IVDs) ("Draft Measures") on November 2 for public comments through November 20.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    Major Medical Device Changes In China Introduced By The 2018 Draft Amendment To The "Regulations On The Supervision And Administration Of Medical Device"*

    Following the issuance of the "Opinions on Deepening the Reform of Examination and Approval System and Encouraging Innovation in the Industries of Pharmaceuticals and Medical Devices"
    ChinaFood, Drugs, Healthcare, Life Sciences
    Reed Smith (Worldwide)
    Reed Smith (Worldwide)
  • Article

    China's New Policies On Foreign Investment In Healthcare And Biotechnology: Catalyzing Innovation And Strengthening Patent Protection

    In early September 2024, China announced two significant policy changes aimed at further opening its healthcare and biotechnology sectors to foreign investment.
    ChinaIntellectual Property
    Lusheng Law Firm
    Lusheng Law Firm
  • Article

    중국 베이징 지식재산권법원, 최초의 의약품 허가특허연계제도 소송 판결 선고

    2022년 4월 15일, 중국 베이징 지식재산권법원은 원고 중외제약주식회사가 피고...
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    China Announced Technology Ethics Review Measures (Trial)

    On 8 October 2023, the Ministry of Science and Technology of the People's Republic of China announced the above measures...
    ChinaTechnology
    Toby Mak
    Toby Mak
  • Article

    2026 Sees China's Biotech Scene Continuing Its Ascent – But Could US Developments Mean Clouds On The Horizon?

    In recent years, China's biotech scene has risen in prominence with its innovative R&D and promising pipelines commanding big pharma's attention. In this blog, we take a look at this trend, which sees China-related deals and investment continuing to flow, as well as the recent developments in the US, with draft legislation being proposed that seeks to impose restrictions which would impact transactions between US pharma companies and Chinese biotechs. 
    GlobalFood, Drugs, Healthcare, Life Sciences
    Herbert Smith Freehills Kramer LLP
    Herbert Smith Freehills Kramer LLP
  • Article

    中国、医療用マイクロナノロボットの開発で新たな進展

    哈爾浜(ハルビン)工業大学と哈爾浜医科大学の科学研究者が共同開発したクマムシ型医療用 マイクロナノロボットが、静脈高速血流環境
    ChinaFood, Drugs, Healthcare, Life Sciences
    Kangxin
    Kangxin
  • Showing 81–100 of 332 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics